This section gives more detail on the tax considerations when looking to expand overseas, together with market access and intellectual property insight overseas.

GNMA 10: Policy and public affairs for life science companies
GNMA 9: Supranational HTAs
GNMA 8: Market access for medtech, diagnostics and digital technologies in the UK
GNMA 7: Impact of Brexit on the regulatory approval process for medicines in the UK
GNMA 6: Impact of conditional approval and approval under exceptional circumstances on national pricing and reimbursement
GNMA 5: Learning from previous NICE consultations
GNMA 4: Cell and Gene Therapies – innovative contracting trends in Europe
GNMA 3: How can early access schemes support accelerated patient access in Europe?
GNMA 2: Top five reasons why products fail to achieve a positive NICE recommendation
GNMA 1: Improving access to orphan medicines
GNT 35: Tax Implications of Brexit on the Pharmaceutical Industry
GNT 51: Double Tax Treaties
GNT 43: Tax Residence
GNT 33: Diverted Profits Tax
GNT 32: Setting up in the US
GNT 24: Intercompany Agreements for Transfer Pricing
GNT 23: Permanent Establishments
GNT 14: Benefits of Incorporating in the UK
GNT 13: Expansion into New Territories
GNT 11: Transfer Pricing Essentials
GNT 7: Patent Box

International Expansion

As the organisation looks to expand overseas this workshop highlights some essential matters to consider.

Sign-Up For Free

Sign-up to receive up-to-date information and advice on tax developments within your industry.

Sign-up for free